Table 1.
Characteristics of study population.
| Drug-naïve (n = 35) |
ARV failure (n = 66) |
*p-Value | |
|---|---|---|---|
| Age (months) | |||
| Median (IQR)a | 58.0 (12–102) | 137.0 (95.7–169.5) | 0.15 |
| Gender – n (%) | |||
| Female | 22 (62.9) | 29 (43.9) | 0.07 |
| Male | 13 (37.1) | 37 (56.1) | |
| Origin – n (%) | |||
| CEDAPb | 28 (80.0) | 46 (69.7) | 0.26 |
| HUPESc | 7 (20.0) | 20 (30.3) | |
| Time after diagnosis (months) | |||
| Median (IQR) | 8 (3–53) | 84 (50–110) | 0.06 |
| Duration of ART use (months) | |||
| Median (IQR) | – | 72 (36–96) | – |
| Viral load before genotyping assay | |||
| Median – IQR (log10) | 5.0 (4.1–5.3) | 4.3 (3.7–4.7) | 0.29 |
| Viral load after genotyping assay | |||
| Median – IQR (log10) | 3.4 (0.0–4.0) | 2.3 (0.0–4.1) | 0.25 |
a
IQR, interquartile range.
b
CEDAP, Specialized State Center for Diagnosis, Care and Research.
c
HUPES, Professor Edgard Santos University Hospital.
*
p value; Chi-square test.